Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTx328
- Development stage
- Unknown
- Lead developer
- Primal Therapies
- Modality
- Small Molecules
01
Overview
**PTx328** is a proprietary Primal Therapies pipeline asset described as a small-molecule combination within the company's SMMRT microbial-metabolism platform. Primal Therapies develops SMMRT compositions intended to modulate microbial metabolism, disrupt harmful biofilms, suppress pathogenic microbial growth, and support beneficial microbiome activity. Publicly available information does not disclose PTx328's individual active components, molecular targets, intended disease indication, route of administration, dosage form, or development stage. ([primaltherapies.com](https://primaltherapies.com/our-pipeline/))
Beyond the preview
Go deeper on PTx328.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTx328.